Appointed
Jian Zhang
Independent Director
IBAC ·
IB Acquisition Corp.
John Joyce, Silvia Panigone, and Jian Zhang were appointed to the board of directors of the Company.
Ready 8-Ks
15
Latest filing
October 15, 2026, 4:15 PM ET
Top materiality
0.85
Event mix
other_material ×11 · m_and_a ×2 · regulatory ×1
Sentiment
3 pos · 2 neg · 10 neu
Executive change
recent →
Recent 8-K filings for IBAC
Highest-materiality recent filing
IB Acquisition Corp. enters into $500M business combination with GNQ Insilico Inc.
- Total arrangement consideration of $500M plus potential revenue and share-price earnouts.
- GNQ shareholders to receive SPAC Class A common or exchangeable shares; GNQ management to lead combined company.
-
Board fixed Wednesday, December 16, 2026 at 10:00 a.m. Eastern Time as the 2026 Annual Meeting date, held virtually via live webcast; record date is close of business October 28, 2026.
-
Nasdaq Listing Qualifications notified IB Acquisition Corp on Oct 5, 2026 that it fails Listing Rule 5620(a) for not holding an annual shareholder meeting within 12 months of fiscal year end.
-
Special Meeting held Sept 24, 2026: Extension, Trust Amendment and Adjournment proposals all approved; 3,444,462 shares present, ~69% of stock outstanding at the Aug 27, 2026 record date.
-
IBAC secures $50M equity line, $16.5M PIPE for GNQ merger, amends deal to drop min cash
Equity Purchase Facility: up to $50M from ELOC investor; 36-month commitment period, $675K convertible commitment note at $10/share.
-
IB Acquisition signs $50M equity facility, up to $90M PIPE notes, amends GNQ Insilico merger
Entered equity purchase facility for up to $50M of new Class A shares; issued $675,000 convertible commitment note.
-
IB Acquisition Corp. extends deadline to complete business combination to September 28, 2026
Stockholders approved extension at special meeting on March 25, 2026.
-
IB Acquisition shareholders approve extension to Sept 28, 2026; ~$7.9M redeemed from trust
All three proposals (extension, trust amendment, adjournment) passed with 5,007,821 for, 70,000 against, no abstentions.
-
GNQ Insilico enters collaboration with Fortune 100 tech firm for AI-driven drug discovery
GNQ Insilico signed a Joint Initiative Agreement with a Fortune 100 global technology company.
-
IB Acquisition Corp. enters into $500M business combination with GNQ Insilico Inc.
Total arrangement consideration of $500M plus potential revenue and share-price earnouts.
-
IBAC extends business combination deadline to March 2026; ~$106M redeemed, trust drops to ~$15.8M
Stockholders approved extension from Sept 28, 2025 to March 28, 2026 for initial business combination.
-
IB Acquisition Corp. dismisses UHY, appoints MaloneBailey as auditor
UHY LLP dismissed as independent auditor effective April 22, 2024, after Audit Committee approval.
-
Dismissed UHY LLP as independent auditor effective April 22, 2024; appointed MaloneBailey LLP on April 24, 2024.
-
IB Acquisition Corp. units to separate into common stock and rights on May 1, 2024
Units (IBACU) cease trading May 1; common stock (IBAC) and rights (IBACR) trade separately on Nasdaq.
-
IPO of 11,500,000 units at $10.00/unit, gross proceeds $115,000,000; includes full over-allotment.
-
IB Acquisition Corp. closes $115M SPAC IPO; trust funded with $115.575M
Sold 11.5M units at $10/unit (including full over-allotment) for gross proceeds of $115M.
Executive changes
Appointed
Silvia Panigone
Independent Director
IBAC ·
IB Acquisition Corp.
John Joyce, Silvia Panigone, and Jian Zhang were appointed to the board of directors of the Company.
Appointed
John Joyce
Independent Director
IBAC ·
IB Acquisition Corp.
John Joyce, Silvia Panigone, and Jian Zhang were appointed to the board of directors of the Company.
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material